Table 3.
Analysis of time to first CID by selected eosinophil cut-offs (pooled analysis; full study duration)
| Cut-off, ×109/L (% ≤) | Lower stratum | Upper stratum | ||||
|---|---|---|---|---|---|---|
| BUD/FORM 160/4.5 μg bid | FORM 4.5 μg bid |
HR (95% CI) | BUD/FORM 160/4.5 μg bid | FORM 4.5 μg bid |
HR (95% CI) | |
| 0.10 (25.2) | 201/285 (70.5) | 199/291 (68.4) | 0.97 (0.80–1.18) | 569/857 (66.4) | 633/853 (74.2) | 0.67 (0.60–0.75) |
| 0.15 (44.8) | 350/503 (69.6) | 373/520 (71.7) | 0.82 (0.71–0.95) | 420/639 (65.7) | 459/624 (73.6) | 0.68 (0.59–0.77) |
| 0.20 (60.9) | 466/675 (69.0) | 519/718 (72.3) | 0.78 (0.69–0.88) | 304/467 (65.1) | 313/426 (73.5) | 0.69 (0.59–0.80) |
| 0.25 (73.1) | 560/818 (68.5) | 613/852 (71.9) | 0.78 (0.69–0.87) | 210/324 (64.8) | 219/292 (75.0) | 0.64 (0.53–0.78) |
| 0.30 (79.9) | 616/896 (68.8) | 670/931 (72.0) | 0.79 (0.71–0.88) | 154/246 (62.6) | 162/213 (76.1) | 0.57 (0.46–0.71) |
| 0.35 (85.2) | 659/965 (68.3) | 708/983 (72.0) | 0.77 (0.69–0.86) | 111/177 (62.7) | 124/161 (77.0) | 0.58 (0.45–0.75) |
Numbers shown: event/total (%)
bid, twice daily; BUD Budesonide, CID Clinically Important Deterioration, CI Confidence interval, FORM Formoterol, HR Hazard ratio